Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Interventional Radiology in Cancer Treatment
share announcement

Interventional Radiology in Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1861

Special Issue Editors

Dr. Sarah B. White

E-Mail Website
Guest Editor
Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA
Interests: interventional oncology; liver directed therapy
Dr. Amy C. Taylor

E-Mail Website
Guest Editor
Department of Radiology and Medical Imaging, University of Virginia Health, Charlottesville, VA, USA
Interests: interventional oncology; women’s health

Special Issue Information

Dear Colleagues,

Since the first intraarterial liver cancer therapy was performed by Ryusaku Yamada in 1977 and the first percutaneous ablation was performed by Luigi Solbiati in 1982, the field of Interventional Oncology (IO) has grown exponentially. A specialty built on innovation, creativity, and disruptive approaches to medical care has now been adopted worldwide and is practiced as the fourth pillar of cancer care alongside medical oncology, surgical oncology, and radiation oncology. IO therapies for hepatocellular carcinoma (HCC), metastatic neuroendocrine tumors (mNET), and renal cell carcinoma (RCC) have been incorporated into the respective Barcelona Clinic Liver Cancer (BCLC) and National Comprehensive Cancer Network (NCCN) guidelines. Due to the explosion of new technologies and rapid expansion of treatment modalities, keeping referring physicians and patients apprised with regard to what Interventional Radiology can offer can be challenging. This Special Issue will elucidate the current cutting-edge technologies and therapies IO offers, as well as the evidence supporting them.

We look forward to receiving your contributions.

Dr. Sarah B. White
Dr. Amy C. Taylor
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional radiology
  • interventional oncology
  • hepatocellular carcinoma
  • chemoembolization
  • radioembolization
  • ablation
  • cholangiocarcinoma
  • metastatic disease
  • neuroendocrine tumor
  • breast cancer

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2066 KiB  
Article
Transarterial Bleomycin–Lipiodol Chemoembolization for the Treatment of Giant Hepatic Hemangiomas: An Assessment of Effectiveness
by Arkadiusz Kacała, Mateusz Dorochowicz, Adrian Korbecki, Michał Sobański, Michał Puła, Dariusz Patrzałek, Dariusz Janczak and Maciej Guziński
Cancers 2024, 16(2), 380; https://doi.org/10.3390/cancers16020380 - 16 Jan 2024
Cited by 1 | Viewed by 792
Abstract
This study evaluates the effectiveness of superselective transcatheter arterial chemoembolization (TACE) using a bleomycin–lipiodol emulsion in treating giant hepatic hemangiomas. A retrospective review included 31 patients with a mean age of 53 ± 10.42 years who underwent TACE from December 2014 to October [...] Read more.
This study evaluates the effectiveness of superselective transcatheter arterial chemoembolization (TACE) using a bleomycin–lipiodol emulsion in treating giant hepatic hemangiomas. A retrospective review included 31 patients with a mean age of 53 ± 10.42 years who underwent TACE from December 2014 to October 2022, with follow-up imaging examinations to assess outcomes. Technical success was defined as successful embolization of all feeding arteries, and clinical success was defined as a reduction in hemangioma volume by 50% or more on follow-up imaging. This study observed a 100% technical success rate. Post-embolization syndrome was common, and two cases of asymptomatic hepatic artery dissection were noted. Clinical success was achieved in 80.6% of patients, with significant volume reduction observed in the majority. Conclusively, superselective transcatheter arterial chemoembolization with bleomycin–lipiodol emulsions is presented as a viable and effective treatment option for giant hepatic hemangiomas. With no procedure-related mortality and significant volume reduction in most cases, this method offers a promising alternative to surgical intervention. This study’s findings suggest a need for further exploration and validation in larger-scale prospective studies. Full article
(This article belongs to the Special Issue Interventional Radiology in Cancer Treatment)
►▼ Show Figures

Graphical abstract

14 pages, 7541 KiB  
Article
Technical and Clinical Outcomes of Laparoscopic–Laparotomic Hepatocellular Carcinoma Thermal Ablation with Microwave Technology: Case Series and Review of Literature
by Riccardo Muglia, Paolo Marra, Domenico Pinelli, Ludovico Dulcetta, Francesco Saverio Carbone, Alessandro Barbaro, Antonio Celestino, Michele Colledan and Sandro Sironi
Cancers 2024, 16(1), 92; https://doi.org/10.3390/cancers16010092 - 24 Dec 2023
Viewed by 829
Abstract
Purpose: To evaluate technical and clinical outcomes of intraoperative (laparoscopic/laparotomic) microwave ablation on HCC. Materials and Methods: This is a retrospective single-center study evaluating consecutive patients treated for very early/early-stage HCC with intraoperative microwave ablation from 1 July 2017 to 30 June 2023. [...] Read more.
Purpose: To evaluate technical and clinical outcomes of intraoperative (laparoscopic/laparotomic) microwave ablation on HCC. Materials and Methods: This is a retrospective single-center study evaluating consecutive patients treated for very early/early-stage HCC with intraoperative microwave ablation from 1 July 2017 to 30 June 2023. In these patients, a percutaneous US-guided approach was excluded due to the nodule’s suboptimal visibility or harmful location and liver resection for a deep position or adherences. Data about the clinical stage, surgical approach, liver pathology and nodules characteristics, technical success, complications, and follow-up were collected. Technical success was intended as the absence of locoregional persistence at follow-up CT/MRI controls. Results: A total of 36 cirrhotic patients (M:F = 30:6, median age 67 years) were enrolled; 18/36 (50%) had a single nodule, 13/36 (36%) had two, 4/36 had three (11%), and 1/36 had four (3%). Among the patients, 24 (67%) were treated with laparoscopy, and 12/36 (33%) with a laparotomic approach. Sixty HCCs of 16.5 mm (6–50 mm) were treated for 7 min (2–30 min) with 100 W of power. A total of 55 nodules (92%) were treated successfully and showed no residual enhancement at the first postoperative follow-up; the other 5/60 (8%) underwent chemo/radioembolization. There was one complication (3%): a biliary fistula treated with percutaneous drainage and glue embolization. The average hospital stay was 3.5 days (1–51 days), and patients were followed up on average for 238 days (13–1792 days). During follow-up, 5/36 patients (14%) underwent liver transplantation, 1/36 (2%) died during hospitalization and 1 after discharge. Conclusions: Laparoscopic/laparotomic intraoperative HCC MW ablation is feasible in patients unsuitable for percutaneous approach or hepatic resection, with rare complications and with good technical and clinical outcomes. Full article
(This article belongs to the Special Issue Interventional Radiology in Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop